Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age at the time of study randomization.~* Histologically confirmed metastatic and/or unresectable GIST.~* Measurable disease on CT or MRI as defined by RECIST.~* Documented radiographic progression or intolerance to imatinib and sunitinib.~* Clinical failure of the most recent prior therapy for GIST. Note: There is no limit to the number of prior therapies a patient may have received.~* Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1.~* Hemoglobin ≥ 8.0 g/dL (80 g/L).~* Absolute Neutrophil Count ≥ 1500/µL (1.5 x 109/L).~* Platelets ≥ 100,000 /µL (100 x 109/L).~* ALT and AST ≤ 2.5 x upper limit of normal (ULN), or ≤ 5.0 x ULN if considered secondary to liver metastases.~* Alkaline phosphatase ≤ 2.5 x ULN, or ≤ 5.0 x ULN if considered secondary to liver metastases.~* Serum bilirubin ≤ 1.5 x ULN.~* PT and PTT ≤ 1.5 x ULN unless the patient is receiving warfarin. If the patient is receiving warfarin, the INR must be within therapeutic range.~* Serum creatinine ≤ 1.5 x ULN.~Exclusion Criteria:~* Previous administration of other known heat shock protein 90 (Hsp90) inhibitors.~* Surgery, radiotherapy, or lesion ablative procedure to the only area of measurable disease.~* Initiation or discontinuation of concurrent medication that is a potent CYP3A inhibitor less than 2 weeks prior to administration of IPI-504 or placebo.~* History of any of the following within the last 6 months: cardiac disease such as acute coronary syndrome or unstable angina, symptomatic congestive heart failure, uncontrolled hypertension, cirrhotic liver disease, cerebrovascular accident, or any other significant co-morbid condition or disease which, in the judgment of the investigator, would place the patient at undue risk or interfere with the study.~* Grade 3 or 4 hemorrhagic event within the last 6 months.~* Known human immunodeficiency virus positivity.~* Sinus bradycardia (resting heart rate \< 50 bpm) secondary to intrinsic conduction system disease.~* QTcF ≥ 470 milliseconds, or previous history of clinically significant QTc prolongation while taking other medications.~* History of prior malignancies within the past 3 years other than non-melanomatous skin cancers that have been controlled, prostate cancer that has been treated and has not recurred, non-muscle-invasive bladder cancer, and carcinoma in situ of the cervix.~* Active or recent history (within 3 months) of keratitis or keratoconjunctivitis confirmed by ophthalmology or optometry exam.~* Presence of Left Bundle Branch Block, Right Bundle Branch Block plus left anterior hemiblock, bifascicular block, or 3rd degree heart block. This does not include patients with a history of these events with adequate control by pacemaker.~* Known CNS metastases.~* Women who are pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IPI-504 (Type: EXPERIMENTAL): retaspimycin hydrochloride (IPI-504) plus best supportive care
- Placebo (Type: PLACEBO_COMPARATOR): Placebo plus best supportive care

Based on this trial design, predict the completion outcome and termination type (if applicable).